Login to Your Account



Other News To Note


Friday, June 28, 2013
Immune Design Inc., of Seattle, and Medicago Inc., of Quebec City, entered a license agreement providing Medicago the use and commercialization of Immune Design's synthetic Toll-like receptor 4 agonist, Glucopyranosyl Lipid A (GLA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription